Compare NEULAND LABS with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS ELDER PHARMA NEULAND LABS/
ELDER PHARMA
 
P/E (TTM) x 62.6 -0.2 - View Chart
P/BV x 4.7 0.1 4,691.7% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 NEULAND LABS   ELDER PHARMA
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
ELDER PHARMA
Jun-14
NEULAND LABS/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs754380 198.3%   
Low Rs247188 131.5%   
Sales per share (Unadj.) Rs594.5491.2 121.0%  
Earnings per share (Unadj.) Rs12.6-3.2 -397.1%  
Cash flow per share (Unadj.) Rs37.014.4 256.9%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs553.4376.5 147.0%  
Shares outstanding (eoy) m12.8320.54 62.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.80.6 145.6%   
Avg P/E ratio x39.6-89.3 -44.4%  
P/CF ratio (eoy) x13.519.7 68.6%  
Price / Book Value ratio x0.90.8 119.9%  
Dividend payout %15.80-   
Avg Mkt Cap Rs m6,4215,833 110.1%   
No. of employees `0001.3NA-   
Total wages/salary Rs m1,2362,179 56.7%   
Avg. sales/employee Rs Th5,949.4NM-  
Avg. wages/employee Rs Th963.8NM-  
Avg. net profit/employee Rs Th126.4NM-  
INCOME DATA
Net Sales Rs m7,62710,089 75.6%  
Other income Rs m39257 15.1%   
Total revenues Rs m7,66610,346 74.1%   
Gross profit Rs m1,019-792 -128.7%  
Depreciation Rs m313361 86.6%   
Interest Rs m2162,756 7.8%   
Profit before tax Rs m529-3,653 -14.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m367125 293.3%   
Profit after tax Rs m162-65 -248.0%  
Gross profit margin %13.4-7.8 -170.2%  
Effective tax rate %69.4-3.4 -2,024.9%   
Net profit margin %2.1-0.6 -328.1%  
BALANCE SHEET DATA
Current assets Rs m5,1529,240 55.8%   
Current liabilities Rs m3,5769,998 35.8%   
Net working cap to sales %20.7-7.5 -275.1%  
Current ratio x1.40.9 155.9%  
Inventory Days Days10546 226.9%  
Debtors Days Days9160 151.6%  
Net fixed assets Rs m3,96910,124 39.2%   
Share capital Rs m129206 62.7%   
"Free" reserves Rs m6,9715,582 124.9%   
Net worth Rs m7,1007,734 91.8%   
Long term debt Rs m7744,889 15.8%   
Total assets Rs m12,31022,882 53.8%  
Interest coverage x3.5-0.3 -1,061.5%   
Debt to equity ratio x0.10.6 17.2%  
Sales to assets ratio x0.60.4 140.5%   
Return on assets %3.111.8 26.1%  
Return on equity %2.3-0.8 -270.2%  
Return on capital %9.522.3 42.4%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m5,187307 1,691.7%   
Fx outflow Rs m1,593125 1,271.2%   
Net fx Rs m3,594181 1,982.3%   
CASH FLOW
From Operations Rs m57311,754 4.9%  
From Investments Rs m-487-561 86.9%  
From Financial Activity Rs m-55-6,762 0.8%  
Net Cashflow Rs m334,432 0.7%  

Share Holding

Indian Promoters % 36.3 39.6 91.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 63.7 7.5 849.7%  
FIIs % 0.0 16.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 36.1 176.5%  
Shareholders   12,705 16,479 77.1%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare NEULAND LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


May 6, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 5-YR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS